OnchocerciasisPhase 4EKAIONCT07145736
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
A Phase 4 study testing Moxidectin and Ivermectin in people with Onchocerciasis and Ascaris Lumbricoides Infection, run by Kirby Institute at 1 site in Angola.
Trial summary
This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Read more about this study
- Who is it for?
- Ages 5 years and olderHealthy volunteers can take part
- Conditions the study is for
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection
- What is being tested?
- Moxidectin and Ivermectin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52,000 participants
- Where
- 1 siteAngola
- Study dates
- 4 Aug 2025to 30 Jun 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Male or female children and adults
- Residents in the villages selected for MDA treatment
Who cannot join
- Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height
- Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above).
- Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age
- Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)
- Know allergy to ivermectin or moxidectin
- Attending other clinical trials during the study
Show all 11Show fewer
- Pregnant
- Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment
- Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether
- Has an illness that makes them too sick or weak to get out of bed
- Currently hospitalized
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Angola1 site, 1 recruiting
- Recruiting
Villages in Andulo and Nharea Municipalities
Andulo, Bíe Province
Marta Palmeirim, PhD, +351 916 563 622, mpalmeirim@kirby.unsw.edu.au
About this study
Official title: Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial
This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.
The trial aims to answer the following key questions:
Read more
- How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?
- Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?
- Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?
- How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?
- How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?
The study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.
- Conditions
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections, Scabies
- Being tested
- Moxidectin, Ivermectin
- Medical subject headings
- Onchocerciasis, Trichuriasis, Hookworm Infections, Scabies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MoxidectinDrug
2 mg tablets
IvermectinDrug
3 mg tablets
| Study group | Role | What they receive |
|---|---|---|
| Moxidectin | Experimental | Single oral dose of moxidectin treatment 8 mg (4 tablets of 2 mg of moxidectin), once per year Receives: Drug: Moxidectin |
| Ivermectin | Active comparator | Single oral dose of ivermectin treatment with approximately 150 µg/kg determined based on height (between 1 and 4 tablets of 3 mg of ivermectin), once per year Receives: Drug: Ivermectin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Onchocerca volvulus microfilariae
Prevalence of O. volvulus microfilariae at 36 months in skin snips, the marker most likely to show change in the shorter term as demonstrated by the therapeutic trials
Measured: 36 months after the first intervention
Secondary outcomes (15)
Prevalence of O. volvulus microfilaria/mg skin
Measured: 12, 24 and 36 months after the first intervention
Microfilariae density (mean, median)
Measured: 12, 24 and 36 months after the first intervention
Prevalence of nodules
Measured: 12, 24 and 36 months after the first intervention
Prevalence of onchocerciasis skin disease
Measured: 12, 24 and 36 months after the first intervention
Proportion of black flies with infective O. volvulus larvae
Infection assessed based on all 3 are markers recommended by WHO to define population-level elimination
Measured: 12, 24 and 36 months after the first intervention
Prevalence of anti-Ov-16
Measured: 12, 24 and 36 months after the first intervention
Prevalence of Ascaris lumbricoides
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Intensity of Ascaris lumbricoides infection
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Prevalence of Trichuris trichiura
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Intensity of Trichuris trichiura infection
Measured through qPCR
Measured: Baseline and 12, 24 and 36 months after the first intervention
Prevalence of hookworm
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Intensity of hookworm infection
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Prevalence of Strongyloides stercoralis
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Intensity of Strongyloides stercoralis infection
Measured through qPCR
Measured: 12, 24 and 36 months after the first intervention
Prevalence of scabies/impetigo
Measured: 12, 24 and 36 months after the first intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2025
- Study start4 Aug 2025
- Primary completion31 Mar 2029 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OnchocerciasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Clusters of villages are assigned to either ivermectin or moxidectin in parallel for the duration of the study.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 52,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kirby Institute
- Sponsor type
- Other government
- Collaborators
- Emory University, La Trobe University, Murdoch Childrens Research Institute, Medicines Development for Global Health, University of Melbourne, Swiss Tropical & Public Health Institute, University of Ottawa, The Mentor Initiative, Erasmus Medical Center, Ministry of Health, Angola, The END Fund, Center for Research on Filariasis and Other Tropical Diseases, Cameroon, World Health Organization
- Responsible party
- Sponsor
- Investigators
- Susana V Nery, PhD, Principal investigator, Kirby Institute, University of New South Wales, Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07145736
- Sponsor's protocol ID
- KirbyI
- Acronym
- EKAIO
- Status last verified
- Nov 2025
- First submitted
- 21 Aug 2025
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial
- ClinicalTrials.gov ID
- NCT07145736
- Acronym / sponsor ID
- EKAIO / KirbyI
- Conditions
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections, Scabies
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 52,000 participants (estimated)
- Lead sponsor
- Kirby InstituteOther government
- Collaborators
- Emory University, La Trobe University, Murdoch Childrens Research Institute, Medicines Development for Global Health, University of Melbourne, Swiss Tropical & Public Health Institute, University of Ottawa, The Mentor Initiative, Erasmus Medical Center, Ministry of Health, Angola, The END Fund, Center for Research on Filariasis and Other Tropical Diseases, Cameroon, World Health Organization
- Study start
- 4 Aug 2025 (actual)
- Primary completion
- 31 Mar 2029 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 28 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.
The trial aims to answer the following key questions:
- How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?
- Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?
- Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?
- How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?
- How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?
The study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Clusters of villages are assigned to either ivermectin or moxidectin in parallel for the duration of the study.
| Arm | Type | Receives |
|---|---|---|
| Moxidectin | Experimental | Drug: MoxidectinSingle oral dose of moxidectin treatment 8 mg (4 tablets of 2 mg of moxidectin), once per year |
| Ivermectin | Active comparator | Drug: IvermectinSingle oral dose of ivermectin treatment with approximately 150 µg/kg determined based on height (between 1 and 4 tablets of 3 mg of ivermectin), once per year |
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Male or female children and adults
- Residents in the villages selected for MDA treatment
Key exclusion criteria (11 listed)
- Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height
- Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above).
- Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age
- Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)
- Know allergy to ivermectin or moxidectin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Moxidectin2 mg tablets | Drug | Moxidectin |
| Ivermectin3 mg tablets | Drug | Ivermectin |
Primary outcome
Prevalence of Onchocerca volvulus microfilariae
Time frame: 36 months after the first intervention
Prevalence of O. volvulus microfilariae at 36 months in skin snips, the marker most likely to show change in the shorter term as demonstrated by the therapeutic trials
15 secondary outcomes
Prevalence of O. volvulus microfilaria/mg skin
Time frame: 12, 24 and 36 months after the first intervention
Microfilariae density (mean, median)
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of nodules
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of onchocerciasis skin disease
Time frame: 12, 24 and 36 months after the first intervention
Proportion of black flies with infective O. volvulus larvae
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of anti-Ov-16
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of Ascaris lumbricoides
Time frame: 12, 24 and 36 months after the first intervention
Intensity of Ascaris lumbricoides infection
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of Trichuris trichiura
Time frame: 12, 24 and 36 months after the first intervention
Intensity of Trichuris trichiura infection
Time frame: Baseline and 12, 24 and 36 months after the first intervention
Prevalence of hookworm
Time frame: 12, 24 and 36 months after the first intervention
Intensity of hookworm infection
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of Strongyloides stercoralis
Time frame: 12, 24 and 36 months after the first intervention
Intensity of Strongyloides stercoralis infection
Time frame: 12, 24 and 36 months after the first intervention
Prevalence of scabies/impetigo
Time frame: 12, 24 and 36 months after the first intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Onchocerciasis
RecruitingObservational study
Host Response to Infection and Treatment in Filarial Diseases
Filariasis, Helminthiasis
Recruiting
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Onchocerciasis (River Blindness), Schistosomiasis
Not yet recruiting
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Active, not recruitingPhase 3
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Onchocerciasis
Active, not recruitingPhase 2
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
Onchocercal Subcutaneous Nodule, Onchocerciasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Susana V Nery, PhD principal investigator
Kirby Institute, University of New South Wales, Australia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Moxidectin and Ivermectin in people with Onchocerciasis and Ascaris Lumbricoides Infection, run by Kirby Institute at 1 site in Angola.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Angola. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Susana V Nery, PhD (+61467076047, snery@kirby.unsw.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Onchocerca volvulus microfilariae (time frame: 36 months after the first intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.